Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Operating Leases (2019 - 2025)

Abeona Therapeutics has reported Operating Leases over the past 7 years, most recently at $4.1 million for Q4 2025.

  • Quarterly results put Operating Leases at $4.1 million for Q4 2025, up 24.74% from a year ago — trailing twelve months through Dec 2025 was $4.1 million (up 24.74% YoY), and the annual figure for FY2025 was $4.1 million, up 24.74%.
  • Operating Leases for Q4 2025 was $4.1 million at Abeona Therapeutics, down from $4.3 million in the prior quarter.
  • Over the last five years, Operating Leases for ABEO hit a ceiling of $8.5 million in Q2 2022 and a floor of $3.0 million in Q2 2024.
  • Median Operating Leases over the past 5 years was $4.4 million (2021), compared with a mean of $5.0 million.
  • Biggest five-year swings in Operating Leases: soared 80.75% in 2022 and later tumbled 49.48% in 2024.
  • Abeona Therapeutics' Operating Leases stood at $7.6 million in 2021, then dropped by 22.57% to $5.9 million in 2022, then fell by 24.8% to $4.4 million in 2023, then decreased by 25.9% to $3.3 million in 2024, then rose by 24.74% to $4.1 million in 2025.
  • The last three reported values for Operating Leases were $4.1 million (Q4 2025), $4.3 million (Q3 2025), and $4.0 million (Q2 2025) per Business Quant data.